Urethral Discharge: Causes, Clinical Approach, Treatment and Follow-up

Post focus: Approach to urethral discharge (urethritis) — causes, symptom recognition, focused examination, investigations, syndromic and laboratory-guided management, doses, partner services, follow-up and prevention.

Learning objectives

• Define urethral-discharge syndrome and distinguish urethritis from dysuria without urethral inflammation.
• Recognise gonococcal and non-gonococcal urethritis, mixed infection, extragenital infection and important non-STI differentials.
• Take a respectful, confidential sexual history; examine correctly, including gentle urethral milking when appropriate.
• Select and interpret microscopy, Gram stain, NAAT, culture and antimicrobial-susceptibility testing (AST), including specimen-site decisions.
• Give safe empiric treatment while awaiting tests, adapt treatment to pregnancy, allergy, HIV, renal/hepatic disease and local guidelines, and avoid inappropriate antibiotic use.
• Manage partners, abstinence, HIV/syphilis/hepatitis testing, retesting, test-of-cure and persistent/recurrent symptoms.

1. What is urethral discharge syndrome?

Urethral discharge syndrome is abnormal mucoid or purulent fluid from the urethral meatus, usually accompanied by dysuria, urethral irritation, itching or urinary frequency. It is a syndrome, not a final microbiological diagnosis. In men it commonly indicates urethritis; women may have urethritis, cervicitis or vaginal discharge that is mistaken for urethral discharge. Syndromic care is valuable where testing is unavailable, but laboratory confirmation should be obtained whenever feasible because gonorrhoea resistance, mixed infections and non-infectious mimics are important.

Globally, the major causes are Neisseria gonorrhoeae (gonococcal urethritis) and Chlamydia trachomatis (non-gonococcal urethritis, NGU). Other causes include Mycoplasma genitalium, Trichomonas vaginalis, herpes simplex virus, adenovirus and less commonly enteric bacteria or organisms introduced by insertive anal intercourse. A patient can have more than one pathogen at once.

2. Core terminology

3. Causes and mechanisms

3.1 Sexually transmitted causes

3.2 Non-sexually transmitted and non-infectious causes

• Trauma from vigorous sex, instrumentation, catheterisation or foreign-body insertion.
• Chemical irritation from soaps, antiseptics, spermicides, lubricants or topical medications.
• Urinary-tract infection, especially with frequency, urgency, suprapubic pain or positive urine culture.
• Balanitis, phimosis, meatal stenosis, urethral stricture or periurethral abscess.
• Prostatitis or chronic pelvic-pain syndrome (perineal pain, painful ejaculation, voiding symptoms persisting over three months).
• Reactive arthritis, inflammatory disease and, rarely, urethral neoplasia.

4. Risk factors and prevention history

• New or multiple partners, partner with an STI, inconsistent condom use, transactional sex or sexual violence.
• Previous STI, HIV, viral hepatitis, limited access to testing, incarceration, adolescent age or substance use that reduces safer-sex decisions.
• Sex at genital, rectal and oral sites; ask about all exposed sites because a urine test alone misses pharyngeal/rectal infection.
• Recent antibiotics, prior gonorrhoea, known local resistance, allergy history and treatment adherence.
• Pregnancy or possibility of pregnancy, which changes drug selection and urgency.

5. Symptoms and signs

5.1 Symptoms to ask about

• Onset, duration, progression, volume, colour, odour and whether discharge is spontaneous or only after urethral milking.
• Burning dysuria, meatal itching, urinary frequency/urgency, haematuria or difficulty passing urine.
• Genital ulcers, vesicles, rash, groin swelling, testicular/scrotal pain or swelling, painful ejaculation and perineal pain.
• Rectal pain, tenesmus, bleeding or discharge; sore throat or conjunctivitis after oral exposure.
• Fever, rigors, malaise, migratory joint pain, pustular rash, severe headache or neck stiffness—possible dissemination or sepsis.
• For partners who can become pregnant: last menstrual period, pregnancy possibility, pelvic/lower-abdominal pain, abnormal vaginal bleeding, dyspareunia and post-coital bleeding.

5.2 Examination

1. Explain the examination, obtain consent, offer a chaperone, ensure privacy and use gloves. Avoid judgemental language.
2. Record temperature, pulse, blood pressure, respiratory rate, mental state and hydration. Look for sepsis.
3. Inspect the meatus and glans for spontaneous discharge, erythema, ulcers, vesicles, warts, balanitis, phimosis or trauma.
4. If no discharge is visible, gentle milking from the penile base toward the glans can express material; do not cause forceful pain or trauma.
5. Palpate urethra for tenderness or fluctuance; examine testes, epididymides and spermatic cords for epididymo-orchitis or torsion.
6. Examine inguinal nodes, skin and joints. Check eyes urgently if red/painful or purulent.
7. When cervicitis/vaginal symptoms are present, perform speculum and bimanual examination where trained: discharge from cervical os, friability, cervical motion, uterine/adnexal tenderness.
8. Perform anorectal/oropharyngeal examination and collect site-specific swabs when exposure or symptoms indicate.

6. Emergency red flags and referral

7. Investigations: choose tests that answer the clinical question

8. Immediate clinical approach (a usable flow)

1. Stabilise and triage: ABCDE, vital signs, sepsis screen and pain control. Identify torsion, retention, severe eye disease, DGI, PID and assault.
2. Confirm the syndrome: inspect the meatus; milk gently if necessary; distinguish urethral discharge from vaginal, balanitis or skin secretions.
3. Take the five-P sexual history: partners, practices, protection, past STIs and pregnancy prevention; add sites of exposure, last sexual contact and partner treatment.
4. Collect specimens before antibiotics when this will not delay treatment: NAAT, Gram stain/culture and tests for HIV/syphilis.
5. Treat at the same visit when clinical urethritis is evident or follow-up is uncertain. Use local Uganda guidance and current resistance data.
6. Explain the plan: complete every dose, avoid sex until the patient and partners have completed treatment and symptoms have resolved, return for danger signs, and bring partners for evaluation.
7. Document and notify where required: syndrome, sites tested, drugs/doses, allergies, partner plan, counselling and follow-up date.

9. Treatment principles and dosing

9.1 Empiric uncomplicated urethritis when gonorrhoea and chlamydia are possible

When visible urethral discharge or objective urethritis is present and immediate laboratory confirmation is unavailable, cover gonorrhoea plus chlamydia according to local protocol. A current international example is ceftriaxone 500 mg IM once for weight <150 kg (1 g IM once if ≥150 kg), plus doxycycline 100 mg orally twice daily for 7 days if chlamydia has not been excluded. Uganda facilities may use a different ceftriaxone/cefixime regimen; check the current Uganda Clinical Guidelines and resistance data.

• Observe the injection when possible and document batch/dose.
• If ceftriaxone is unavailable, current international guidance lists cefixime 800 mg orally once as an alternative, but it is less reliable for pharyngeal infection and resistance surveillance is important.
• Do not use cefixime or ceftriaxone as a substitute for chlamydia treatment; add doxycycline unless chlamydia is excluded.

9.2 Nongonococcal urethritis (chlamydia likely)

• Doxycycline 100 mg orally twice daily for 7 days. Counsel to take with water, remain upright and use sun protection; separate from iron/calcium/antacids if possible.
• Alternative when adherence is a serious concern or doxycycline is unsuitable: azithromycin 1 g orally once; efficacy is lower for rectal infection, so follow local guidance and consider test-of-cure in selected cases.
• Another alternative in non-pregnant adults where locally recommended: levofloxacin 500 mg orally once daily for 7 days; consider tendon, QT, CNS, aortic and drug-interaction risks.

9.3 Pregnancy and breastfeeding

Pregnancy changes antibiotic choice and requires obstetric/local-guideline input. Avoid doxycycline and fluoroquinolones unless a specialist determines that benefits outweigh risks. For confirmed/suspected chlamydia, a common pregnancy regimen is azithromycin 1 g orally once (or amoxicillin 500 mg orally three times daily for 7 days where locally recommended). Gonorrhoea in pregnancy is treated with ceftriaxone under current guidance; test of cure and partner treatment are important. Treat and test partners rather than exposing the mother repeatedly to empiric courses.

9.4 Trichomonas-associated urethritis

• Metronidazole 2 g orally once or tinidazole 2 g orally once for men with persistent/recurrent urethritis in settings where T. vaginalis is likely, guided by testing and local policy.
• For women with confirmed trichomoniasis, many current guidelines use metronidazole 500 mg orally twice daily for 7 days. Treat all sex partners and avoid alcohol during metronidazole and for at least 24 hours afterward (longer for tinidazole according to product guidance).

9.5 Herpetic urethritis

For a first clinical episode of genital herpes, a common adult regimen is acyclovir 400 mg orally three times daily for 7–10 days (or valacyclovir 1 g twice daily for 7–10 days), started early and adjusted for renal function. Severe disease, urinary retention, disseminated infection, pregnancy or immunocompromise needs specialist management and possible IV acyclovir.

9.6 Persistent/recurrent NGU

1. Confirm objective inflammation before more antibiotics; symptoms alone are not enough.
2. Check adherence, vomiting, drug interactions and re-exposure to an untreated partner.
3. Test for gonorrhoea/chlamydia, M. genitalium and T. vaginalis where available; consider HSV, adenovirus, UTI and prostatitis.
4. If M. genitalium is confirmed and resistance testing is unavailable, international guidance uses doxycycline 100 mg twice daily for 7 days followed by moxifloxacin 400 mg once daily for 7 days; specialist/local guidance is essential because resistance and safety constraints vary.
5. Refer persistent pain, voiding symptoms or painful ejaculation lasting over three months to urology; consider chronic pelvic-pain syndrome rather than endless antibiotics.

10. Drug safety checklist

11. Partner management and sexual-health package

• With consent and confidentiality, notify and offer evaluation/testing to all partners in the preceding 60 days (or according to the identified infection and national protocol).
• Use patient referral, provider referral, dual notification or expedited partner therapy only where lawful and supported by local policy. Partners need treatment for the actual pathogen, not merely reassurance.
• Advise no vaginal, anal or oral sex until the patient and partners have completed a 7-day regimen and symptoms have resolved, or for 7 days after single-dose therapy.
• Offer condoms and demonstrate correct use; discuss PrEP/PEP eligibility for HIV when relevant, vaccination for hepatitis B and HPV, and contraception/pregnancy intentions.
• Test for HIV and syphilis; offer hepatitis B/C testing according to risk and local policy. Provide linkage, psychosocial support and violence/safeguarding referral.

12. Follow-up and test of cure

• Give a clear return date and written instructions. Review results, symptom resolution, adherence, adverse effects and partner treatment.
• Routine test of cure is not always required for uncomplicated urogenital gonorrhoea treated with recommended ceftriaxone, but is important for pharyngeal infection, pregnancy when advised, alternative regimens, suspected resistance or persistent symptoms. For suspected gonorrhoea treatment failure, obtain culture plus AST and preferably NAAT before retreatment; test of cure is commonly performed 7–14 days after retreatment.
• For chlamydia in pregnancy, perform a test of cure about four weeks after treatment where recommended. Avoid NAAT too soon because non-viable nucleic acid can persist.
• Retest for chlamydia/gonorrhoea/trichomoniasis at approximately three months because reinfection is common, even if the partner was treated.
• Persistent symptoms with no objective inflammation require a broader differential, not automatic antibiotic escalation.

13. Complications to prevent or detect

14. Nursing and health-education interventions

• Provide a non-judgemental, confidential environment; use an interpreter when needed and confirm understanding with teach-back.
• Assess pain, fever, hydration, urinary output, scrotal findings and medication allergy before administration.
• Administer directly observed doses when appropriate, document route/site/time, monitor for anaphylaxis and provide written dosing instructions.
• Teach completion of multidose therapy, doxycycline positioning/sun precautions, metronidazole alcohol avoidance and signs requiring urgent return.
• Offer condoms, partner-notification support, HIV/syphilis testing, vaccinations and referral for PrEP/PEP, sexual violence or mental-health support.
• Maintain accurate records for antimicrobial stewardship and public-health surveillance without disclosing information unnecessarily.

15. Worked clinical cases

Case 1: copious discharge and dysuria

A 24-year-old man has two days of abrupt dysuria and thick yellow discharge after a new partner. Examine the meatus, collect first-void urine/urethral swab for NAAT and culture if available, test HIV/syphilis, treat promptly for gonorrhoea and chlamydia per current local guideline, notify partners from the relevant window and review in one week or sooner if worse. Counsel no sex until both partners complete treatment.

Case 2: persistent symptoms after treatment

A man returns 14 days after doxycycline with burning but no discharge. First check adherence and re-exposure, document objective inflammation, test for gonorrhoea/chlamydia, M. genitalium and trichomonas where available, and assess prostatitis/irritant causes. Do not simply repeat antibiotics based on symptoms alone.

Case 3: discharge plus painful red eye

Purulent conjunctivitis with urethral discharge is an emergency. Obtain specimens without delaying care, urgently involve ophthalmology, give systemic gonococcal treatment according to current guideline (adult conjunctivitis commonly requires ceftriaxone 1 g IM once), irrigate the eye as directed, test/treat partners and assess for dissemination.

16. Quick self-test

1. Why is first-void rather than midstream urine used for urethral NAAT?
2. Name the two most common bacterial causes of urethral discharge.
3. What three steps must be checked before labelling persistent urethritis as treatment failure?
4. List four reasons for urgent referral.
5. How long should sex be avoided after a seven-day regimen?

Further study and source material

• Slideshare: Approach to urethral discharge (history, examination, milking technique, specimens, follow-up and test of cure).
• WHO guidelines for management of symptomatic STIs (syndromic flow charts and practical recommendations).
• Uganda Clinical Guidelines 2023 — confirm the current national urethral-discharge regimen.
• CDC urethritis and cervicitis guidance.
• CDC gonorrhoea treatment and resistance guidance.

Take-home: Confirm the syndrome, collect the right site-specific tests, treat gonorrhoea and chlamydia promptly when indicated, manage partners, screen for HIV/syphilis, identify emergencies, and reassess persistent symptoms objectively rather than repeatedly prescribing antibiotics.